Ibrutinib Powder

Product Details

Ibrutinib powder is used to treat previously treated mantle cell lymphoma. Ibrutinib is an inhibitor of BTK, a key kinase in the B cell signaling receptor pathway, which actually plays a key role in the maturation and development of B cells. It was originally discovered because in the 1950s, a child was found to have a congenital agammaglobulin deficiency, which is actually a congenital enzyme deficiency disease. Later in the 1970s, this gene, the BTK gene, was cloned. It is a gene and a kinase that plays an important role in the differentiation and development of normal B cells.

The phase III clinical trial RESONATE-2 scientific research found that ibrutinib was significantly more effective than the previous treatment in patients with 17P- and TP53 gene mutations who were not cured for a long time. Another scientific study compared ibrutinib with standard FCR (fludarabine, cyclophosphamide, rituximab). The data show that ibrutinib combined with rituximab is better than the traditional FCR chemotherapy regimen in terms of overall survival (OS) and progression-free survival (PFS) in a short time. Therefore, the indication of ibrutinib in chronic lymphocytic leukemia has entered the first line from the relapse or long-term cure of the disease, and it also shows very good efficacy in high-risk patients. Ibrutinib is a small molecule BTK inhibitor that forms covalent bonds with cysteine residues in the active site of BTK, thereby inhibiting the activity of BTK enzymes. Studies have shown that 99% purity ibrutinib powder inhibits malignant B cell proliferation and survival in vivo, as well as cell migration and substrate adhesion in vitro.

Health Benefits

For the treatment of patients with mantle cell lymphoma (MCL) who have received at least one treatment with lenalidomide or other drugs in the early stage.

For the treatment of chronic lymphocytic leukemia (CLL) patients who have received at least one treatment in the past.

For the treatment of chronic lymphocytic leukemia (CLL) patients with del 17p deletion mutation.

For the treatment of Waldenström’s macroglobulinemia (WM), a rare cancer that begins in the body’s immune system. The drug received Breakthrough Therapy Designation for this disease.

For the first-line treatment of patients with chronic lymphocytic leukemia (CLL). This approval, for the first time, provides a chemotherapy-free (chemotherapy-free) first-line treatment option for the CLL population.

Treatment of adult patients with chronic graft-versus-host disease (cGVHD) who have failed previous therapy. This is the first FDA-approved treatment for the disease.